SBIR Phase I: MIcrobial Modulation of Gastrointestinal Digestive Efficiency and Inflammation

这项小型企业创新研究（SBIR）第一阶段项目旨在为公众消费提供一种新的益生菌产品，以解决美国和全球日益严重的肥胖问题以及糖尿病和心脏病等相关健康问题的同时增加。根据疾病预防中心的数据，美国60-65%的成年人超重或肥胖。虽然实施生活方式的改变（饮食调整和增加体力活动）可以改善这种情况，但有充分的证据表明复发会导致额外的体重增加。目前的治疗是有限的，包括手术和药物，有充分的记录健康风险。该产品旨在胃肠道内发挥作用，减少宿主可用的能量，并为消费者提供一种阻止体重增加和降低复发风险的方法，可能对导致健康状况下降和医疗保健成本增加的潜在风险因素进行积极调节。这项研究的更广泛/商业影响将是降低肥胖的高发病率。美国医疗保健成本的上升已经有据可查。这种成本的大部分与肥胖增加有关，肥胖是糖尿病和心脏病等疾病发展的潜在因素，通常与腹围/炎症过程的增加有关。根据世界卫生组织的数据，世界上四分之三的人口依赖某种形式的非药品产品进行保健，这为未来的商业化提供了一个世界范围的营销机会。

This Small Business Innovation Research (SBIR) Phase I project is designed to provide a new probiotic product for public consumption that will address the rising US and global obesity issue and related concurrent increase in health problems such as diabetes and heart disease. According to the Centers for Disease and Prevention, 60-65% of the adult population in the US is overweight or obese. While implementation of lifestyle change (dietary modification and increased physical activity) improves this condition, relapse with additional weight gain is well documented. Current treatments are limited and include surgery and pharmacological agents with well documented health risks. This product is designed to work within the gastrointestinal tract, decreasing the amount of energy available to the host, and providing a means to the consumer to halt weight gain and decrease the risk of relapse, with possible positive modulation of underlying risk factors which contribute to declining health and contribute to increased health care costs. The broader/commercial impacts of this research will be to reduce the high incidence of obesity. The rising cost of health care in the US has been well documented. Much of this cost is associated with increasing obesity, an underlying factor in the development of diseases such as diabetes and heart disease, commonly associated with an increase in abdominal circumference/inflammatory processes. According to the World Health Organization, three-fourths of the world population depends upon some form of non-pharmaceutical product for health care, providing a world-wide marketing opportunity for future commercialization.